Tectonic Therapeutic, Inc. (TECX)
NASDAQ: TECX · Real-Time Price · USD
29.32
-0.37 (-1.25%)
Apr 16, 2026, 12:07 PM EDT - Market open
Tectonic Therapeutic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
60
Market Cap
550.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 418.63M |
| CorMedix | 311.71M |
| Valneva SE | 205.07M |
| ADC Therapeutics | 81.36M |
| Fulcrum Therapeutics | 80.00M |
| Verastem | 30.91M |
| Aclaris Therapeutics | 7.83M |
| Shattuck Labs | 1.00M |
TECX News
- 6 weeks ago - Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 weeks ago - Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board - GlobeNewsWire
- 2 months ago - Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 - GlobeNewsWire
- 6 months ago - Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF - GlobeNewsWire
- 8 months ago - Tectonic Therapeutic to Participate in September Investor Conferences - GlobeNewsWire
- 10 months ago - Tectonic Therapeutic Joins Russell 3000® Index - GlobeNewsWire
- 11 months ago - Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 - GlobeNewsWire
- 1 year ago - Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire